Cargando…
Durapain in symptomatic treatment of severe acute pain: a post-marketing, prospective, multicenter, observational study – PRIME study
OBJECTIVE: To assess the effectiveness, overall tolerability, and gastrointestinal (GI) tolerability of Durapain (fixed dose combination of tramadol hydrochloride immediate release [50 mg] and diclofenac sodium sustained release [75 mg]) in symptomatic treatment of severe acute pain in physician’s r...
Autores principales: | Shah, Kshitij, Chaudhari, Omvijay B, Gupta, Palash, Chaudhuri, R Hom, Kamilya, Ranjan, Kulkarni, Shreedhar S, Subbaiah, S, Sorathia, Zubair H, Billa, Gauri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449136/ https://www.ncbi.nlm.nih.gov/pubmed/28579825 http://dx.doi.org/10.2147/JPR.S123772 |
Ejemplares similares
-
Are trial participants adequately safeguarded by the ethics committees—the Indian scenario?
por: Thakkar, Karan, et al.
Publicado: (2014) -
Tramadol/Diclofenac Fixed-Dose Combination: A Review of Its Use in Severe Acute Pain
por: Shah, Dilip D., et al.
Publicado: (2020) -
The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013) -
Light at the end of the tunnel?: The Great Indian Pharmacoeconomics story
por: Thakkar, Karan B., et al.
Publicado: (2013) -
Practice of Pain Management by Indian Healthcare Practitioners: Results of a Paper Based Questionnaire Survey
por: Billa, Gauri, et al.
Publicado: (2015)